4/26/2013

Esperion Therapeutics said it secured $33 million in a preferred stock funding round led by Longitude Capital and it will use the money to fund clinical trials. The Ann Arbor, Mich.-based firm is developing a cholesterol-lowering drug for patients who can't take statins. The drug, called ETC-1002, is in midstage development.

Full Story:
Xconomy

Related Summaries